Concurrent mutations in tumor protein p53 (TP53) or Kelch‐like ECH‐associated protein 1‐nuclear factor erythroid 2‐related factor 2‐pathway components are linked to poor outcomes in epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC), but the impact of triple mutations remains unclear. Here, EGFR is linked to non-small cell lung carcinoma.